...Drug therapy today is moving from a one-fits-all patient approach towards drug therapies in conjunction with disease specific diagnostics to "personalized medicines" as well as patient centric therapies for different patient populations towards "individualized medicines" With this increased knowledge and understanding existing drug therapies and drug molecules still offer an important pool of molecules for innovative therapeutics. These products which are neither new chemical entities (NCE) nor traditional generics (Gx) are products in between, offering a therapeutic advantage addressing a clinical or patient need.
However, these improved therapeutic products do not have a commonly agreed name and are called "New Therapeutic Entities", "Hybrids", "Supergenerics" or "Added Value Generics".
http://www.rcpe.at/pdfs/Publikationen/Improvedtherapeuticent...

In a recent article European authors have upped the ante by calling products approved under the 505(b)(2) or the closely related EU 'hybrid' procedure, 'Super Generics', while offering "added value generics, new therapeutic entities or hybrids" as alternative names.
blog.camargopharma.com/.../are-505b2s-super-generics-or-what-do-we-...

The term "supergeneric" has been given to the development process for small molecule drugs which offer a therapeutic advantage or differ from me-too generic products. While generic drugs represent a copycat version of the parent drug, supergenerics represent new therapeutic entities that demonstrate improvements in product delivery, design or the manufacturing process.
http://bionity.com/en/news/137617/pharma-s-new-hero-supergen...
...szabadalommal védhető új
gyógyszerkészítmény születhet. A viszonylag kis tőkeerővel, de nagy szellemi potenciállal rendelkező országokban, amilyen péládul Magyarország is, igen fontosak ezek az úgynevezett szupergenerikus vagy generikus plusz készítmények.
http://www.weborvos.hu/adat/humantrade/apr/04_HT_06-09.pdf